Summit Therapeutics to Present Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference – Yahoo Finance

Cambridge, Massachusetts, Jan. 05, 2022 (GLOBE NEWSWIRE) — Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that it will present the Company’s vision and its intended future development pathways at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at approximately 3:45 PM EST. Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Chief Operating Officer and a member of Summit’s Board of Directors, will provide details regarding Summit’s commitments towards its future research and clinical development goals, in addition to its current product pipeline.
The presentation will be available the following day on the home page of our website: https://www.summittxinc.com.
About Summit Therapeutics
The overriding objective of Summit Therapeutics is to create value for patients, hospital caregivers, and community-based healthcare providers, as well as healthcare payers around the world. We seek to create value by developing drugs with high therapeutic efficacy – curing the cause or effect of the patient's condition with minimal or zero disease recurrence or antimicrobial resistance, for the longest extent possible – and minimizing the trauma caused to the patient and healthcare ecosystem by minimizing serious side effects, disease recurrence, and inaccessibility to our treatments as a result of financial or other barriers. Summit Therapeutics, empowered by its Discuva Platform, the Company’s innovative antibiotic discovery engine, and supported by BARDA and CARB-X funding, intends to be the leader in patient-friendly and paradigm-shifting treatments for infectious diseases and other significant unmet medical needs while being an ally to physicians. Our new era, novel mechanism pipeline product candidates are designed with the goal to become the patient-friendly, new-era standard of care, by working in harmony with the human microbiome to treat prospective patients suffering from infectious diseases, initially focusing on Clostridioides difficile infection (CDI). Currently, Summit’s lead product candidate, ridinilazole, is a novel, first-in-class drug engaged in a global Phase III trial program. Commercialization of ridinilazole is subject to regulatory approvals. SMT-738, the second candidate within Summit’s portfolio, is currently in the IND-enabling phase for the treatment of multidrug resistant infections, specifically those caused by carbapenem-resistant Enterobacteriaceae (CRE).
For more information, please visit https://www.summittxinc.com and follow us on Twitter @summitplc. For more information on the Company’s Discuva Platform, please visit https://www.summittxinc.com/our-science/discuva-platform.
Contact Summit Investor Relations:
Dave Gancarz
Head of Stakeholder Relations & Corporate Strategy
[email protected]
General Inquiries:
[email protected]
Summit Forward-looking Statements
Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company’s product candidates, the therapeutic potential of the Company’s product candidates, the potential commercialization of the Company’s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the impact of the COVID-19 pandemic on the Company’s operations and clinical trials and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, global public health crises, including the coronavirus COVID-19 outbreak, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of filings that the Company makes with the Securities and Exchange Commission. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ridinilazole. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

A key clinical trial, an enormous market opportunity, and breakthrough biotechnology could drive returns for shareholders this year.
Yahoo Finance's Jared Blikre reports on the market as stocks tumble after the release of the Federal Open Market Committee's meeting.
A Main Line pharmaceutical company has, for the second time, submitted an application seeking emergency use authorization for its experimental Covid-19 therapy from the Food and Drug Administration NRx Pharmaceuticals (NASDAQ: NRXP) of Radnor is seeking the authorization for the use of its new drug candidate, Zyesami, in critical patients with Covid-19 who are at immediate risk of death from respiratory failure despite treatment with approved therapy including Remdesivir. The company initially sought emergency use approval for Zyesami in a broader group of Covid patients last year, but that application was rejected by the FDA.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-derived therapies, today announced the completion of its Phase 1 clinical trial of 18-MC, the Company's non-hallucinogenic proprietary derivative of ibogaine, being developed for the treatment of indications linked to opioid use disorder. The trial was completed in December 2021 with topline results expected in early 2022.
It's time to abandon today’s obsession with empty growth, the CNBC host says.
This year could be a big one for Novavax (NASDAQ: NVAX). The biotech company fell behind in the coronavirus vaccine race last year. Novavax just completed its data submission to the U.S. Food and Drug Administration (FDA).
Dow loses grip on gains Wednesday and stocks fall to session lows, after the release of the Fed's December meeting minutes show robust discussion around the potential trimming of the central bank's record-sized balance sheet.
Rivian shares are down 6% in early trading Wednesday. News regarding Amazon.com, a Rivian customer and investor, has other Rivian investors vexed.
Technology stocks came under renewed pressure on Wednesday while the Dow set a fresh record high, with investors turning away from tech. and growth stocks in anticipation of higher rates.
Yahoo Finance's Akiko Fujita breaks down why software company stocks like Adobe and Salesforce are declining today.
DoubleLine Capital Founder and CEO Jeffrey Gundlach sits down with Yahoo Finance Live's Brian Sozzi to discuss the probability of a recession in 2023, the Fed, car prices, stock overvaluation, the S&P 500, and China.
Investors seem to be seeing a light at the end of the tunnel with the COVID-19 pandemic despite the present darkness.
Yahoo Finance’s Ines Ferre breaks down how Microsoft is heading for its longest losing streak since September, Sony's new operating company Sony Mobility is entering the EV space, and how Wayfair continues to sink to a 52-week low.
Tilray (NASDAQ: TLRY) shareholders lost ground to the market in December, with the stock slumping 31% compared to a 4% spike in the S&P 500, according to data provided by S&P Global Market Intelligence. Tilray shares had been up more than 200% in early 2021 but finished the year in negative territory compared to a 27% surge in the wider stock market. December brought two important updates on the pot stock's business.
Data analytics stock Palantir Technologies (NYSE: PLTR) dropped 11.8% in December as investors continue to move away from growth stocks with high valuations. Similar stocks, including Splunk (NASDAQ: SPLK) and Alteryx (NYSE: AYX), had very similar charts throughout the month. This indicates that market forces are behind the move, which occurred without any significant news from Palantir.
Stocks fell Wednesday after the minutes from the last FOMC meeting confirmed that the Federal Reserve will begin raising interest rates as its own concerns about inflation grow. The declined 393 points, or 1.1%, after being in the green before the Fed released the minutes from its December meeting. The release of the Fed minutes is usually a dull affair, as they usually do nothing more than confirm what the Fed had already said at its most recent meeting.
U.S. share benchmarks fell as investors analyzed minutes from the Federal Reserve’s recent policy meeting in hopes of new clues about weaning markets off stimulus measures.
From 2019 to the end of 2021, the S&P 500 produced a 103% total return amid a slew of challenging events. Turning the calendar to 2022, investors might be interested in pulling in the reins and shifting toward undervalued dividend stocks that generate passive income. Here's what makes Kinder Morgan (NYSE: KMI) and United Parcel Service (NYSE: UPS) two great options worth considering now.
Shares of cloud computing software giant salesforce.com (NYSE: CRM) were down 6.4% Wednesday as of 12:55 p.m. ET. Salesforce is now down 18% from its all-time high reached in November 2021. There was no specific news from Salesforce that caused this most recent dip.
Bitcoin slid sharply after the Federal Reserve released minutes of its December meeting, with policy makers indicating growing unease over inflation and the potential for interest rates to start rising as soon as this March. Bitcoin was down more than 4% to $44,200, falling from around $46,000 soon after the Fed made the minutes public. Fed officials indicated that inflation readings and tight labor conditions could warrant an interest-rate increase “sooner or at a faster pace than participants had earlier anticipated.”

source